Reduced-intensity allogenic hematopoietic stem cell transplantation for myelodysplastic syndrome
نویسندگان
چکیده
منابع مشابه
Hematopoietic stem cell transplantation for myelodysplastic syndrome.
Allogeneic hematopoietic stem cell transplantation remains the only curative option for myelodysplastic syndrome, but patients with this disease are often older and frail, and treatment-related mortality and morbidity is a major obstacle to be overcome. Treatment of MDS is likely to benefit from the major lines of investigation in the field of allogeneic transplantation, especially intervention...
متن کاملHematopoietic Stem Cell Transplantation for Thalassemia
Thalassemia is an autosomal recessive disorder associated with defective synthesis of the α- or β-chain of hemoglobin. For β-thalassemia major patients, therapeutic options are either monthly red cell transfusions and chelation therapy or allogeneic stem cell transplant. Stem cell transplant is the only curative approach and success is inversely correlated with the degree of iron overload and h...
متن کاملPediatric Hematopoietic Stem Cell Transplantation
The introduction and evolution of hematopoietic stem cell transplantation (HSCT) could be traced back to 1950s, to the studies on interactions among irradiation, covering spleen and bone marrow from it and injection of bone marrow cells. Today, HSCT is considered a well-established, effective and promising means of therapy for various malignant and non-malignant medical conditions, both in chil...
متن کاملAllogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome.
Transplantation is the only known cure for myelodysplastic syndrome (MDS). While some comparative analyses have demonstrated early transplantation to be the preferred strategy for all MDS patients, many of these analyses are biased. Using newly identified prognostic factors and models, a rational approach to transplantation can be undertaken. Factors such as transfusion dependency, cytogenetics...
متن کاملHematopoietic cell transplantation for myelodysplastic syndrome.
Although high-dose chemotherapy may cure a small subset of patients with myelodysplastic syndrome (MDS), allogeneic hematopoietic cell transplantation (HCT) is the only currently available modality that is curative in a large proportion of patients. Approximately 30% to 40% of patients with high-risk MDS and 60% to 80% of patients with low-risk MDS survive long-term in remission. Disease classi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biology of Blood and Marrow Transplantation
سال: 2006
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2005.11.090